L. Bjermer (Lund, Sweden), R. Gosens (Groningen, Netherlands)
Late Breaking Abstract - The duration of anti-inflammatory action of fluticasone furoate (FF) assessed via exhaled nitric oxide (FeNO) in asthmatics following administration of FF/vilanterol (VI). P. Daley-Yates (Greenford, United Kingdom)
| |
A randomized trial of AZD7594 a novel non-steroidal anti-inflammatory drug in asthma patients A. Aggarwal (Wellesley, United States of America)
| |
Molecular evidence of Group 1 innate lymphoid cell activation in the U-BIOPRED cohort S. Pavlidis (London, United Kingdom)
| |
MUC5AC expression decrease correlates with the decline in rates of severe asthma exacerbations post bronchial thermoplasty J. Chakir (Québec, QC, Canada)
| |
Pharmacological characterization of CHF6162, a novel long acting inhaled corticosteroid for the treatment of asthma G. Marchini (Parma, Italy)
| |
Pharmacological properties of novel LTC4 synthase inhibitor P. Glader (Mölndal, Sweden)
| |
Nicotinic alpha-7 receptor stimulation (a7nAChR) inhibited NF-kB/STAT3/SOCS3 pathways in a murine model of asthma. F. Roncon Santana (Diadema, Brazil)
| |
Fevipiprant reduces airway smooth muscle mass in asthmatics via PGD2 receptor antagonism R. Saunders (Leicester, United Kingdom)
| |